{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:19:59Z","timestamp":1793834399932,"version":"4.6.1"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009874","name":"University of Sherbrooke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101305","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:47:45Z","timestamp":1748083665000},"page":"101305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies"],"prefix":"10.1016","volume":"74","author":[{"given":"Sophie","family":"Roux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Debiais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101305_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0010","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.3390\/jcm11113088","article-title":"Newly diagnosed multiple myeloma patients with skeletal-related events and abnormal MRI pattern have poor survival outcomes: a prospective study on 370 patients","volume":"11","author":"Kanellias","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101305_bb0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100999","article-title":"The use of bone-modifying agents in multiple myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101305_bb0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jha2.928","article-title":"Incidence and prevention of skeletal-related events in multiple myeloma patients: a population-based real-world experience","volume":"5","author":"Rora","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101305_bb0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1177\/1078155219881489","article-title":"Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events","volume":"26","author":"Ailawadhi","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2025.101305_bb0040","series-title":"Maladies M\u00e9taboliques Osseuses de l\u2019Adulte, M\u00e9decine-Sciences, Editions Flammarion, Paris, 2008","first-page":"313","article-title":"Myeloma bone disease: new insights in the pathophysiology and therapeutic implications","volume":"Chap. 36","author":"Roux","year":"2008"},{"key":"10.1016\/j.blre.2025.101305_bb0045","first-page":"181","article-title":"[Myeloma bone disease: pathophysiology] L\u2019os du my\u00e9lome multiple","volume":"84","author":"Roux","year":"2017","journal-title":"Physiopathol Rev Rhum (Monogr)"},{"key":"10.1016\/j.blre.2025.101305_bb0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/10428194310001593193","article-title":"The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK ligand expression","volume":"45","author":"Roux","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101305_bb0055","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100646","article-title":"Why do myeloma patients have bone disease? A historical perspective","volume":"41","author":"Borset","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101305_bb0065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1359\/jbmr.2001.16.9.1583","article-title":"The bone remodeling compartment: a circulatory function for bone lining cells","volume":"16","author":"Parfitt","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101305_bb0075","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0085","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0090","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2025.101305_bb0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V97.2.346","article-title":"Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1","volume":"97","author":"Sanz-Rodriguez","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/leu.2013.6","article-title":"Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes","volume":"27","author":"Colombo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0105","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3324\/haematol.2020.253526","article-title":"Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/289458","article-title":"Cellular mechanisms of multiple myeloma bone disease","volume":"2013","author":"Oranger","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.blre.2025.101305_bb0115","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ijc.31817","article-title":"Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers","volume":"144","author":"Sharma","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101305_bb0120","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2011-11-393348","article-title":"Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment","volume":"119","author":"D\u2019Souza","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0125","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1359\/JBMR.050207","article-title":"Annexin II stimulates RANKL expression through MAPK","volume":"20","author":"Li","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0130","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","article-title":"Clinical and prognostic role of annexin A2 in multiple myeloma","volume":"120","author":"Seckinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0135","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0140","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/jbmr.2868","article-title":"Inflammatory osteoclasts prime TNFalpha-producing CD4(+) T cells and express CX(3) CR1","volume":"31","author":"Ibanez","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","article-title":"Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast","volume":"75","author":"Reagan","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12079-022-00674-2","article-title":"Periostin: an emerging activator of multiple signaling pathways","volume":"16","author":"Wang","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.blre.2025.101305_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147837","article-title":"Role of periostin in adhesion and migration of bone remodeling cells","volume":"11","author":"Cobo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2025.101305_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.90","article-title":"High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma","volume":"6","author":"Terpos","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cbin.10219","article-title":"Periostin and transforming growth factor beta-induced protein (TGFbetaIp) are both expressed by osteoblasts and osteoclasts","volume":"38","author":"Merle","year":"2014","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.blre.2025.101305_bb0170","first-page":"181","article-title":"Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model","volume":"28","author":"Kyutoku","year":"2011","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.blre.2025.101305_bb0175","first-page":"13","article-title":"Periostin Exon-21 antibody neutralization of triple-negative breast cancer cell-derived Periostin regulates tumor-associated macrophage polarization and angiogenesis","author":"Fujikawa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101305_bb0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yexcr.2014.01.018","article-title":"Multifunctional ECM proteins in bone and teeth","volume":"325","author":"Ravindran","year":"2014","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.blre.2025.101305_bb0185","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.leu.2403976","article-title":"Human myeloma cells express the bone regulating gene Runx2\/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients","volume":"19","author":"Colla","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0190","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0195","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","article-title":"Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -implications for myeloma bone disease","volume":"93","author":"Dotterweich","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0205","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208884","article-title":"Galectins at a glance","volume":"131","author":"Johannes","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.blre.2025.101305_bb0210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/labinvest.2014.107","article-title":"Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3\/galectin-9 system in the modulation of inflammatory bone destruction","volume":"94","author":"Moriyama","year":"2014","journal-title":"Lab Investig"},{"key":"10.1016\/j.blre.2025.101305_bb0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/cancers11020261","article-title":"Loss of stromal Galectin-1 enhances multiple myeloma development: emphasis on a role in osteoclasts","volume":"11","author":"Muller","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101305_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2017.08.013","article-title":"Galectin-3 as a novel regulator of osteoblast-osteoclast interaction and bone homeostasis","volume":"105","author":"Simon","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0225","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1096\/fj.201700716R","article-title":"Ablation of the mammalian lectin galectin-8 induces bone defects in mice","volume":"32","author":"Vinik","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.blre.2025.101305_bb0230","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302348","article-title":"Galectin-8 modulates human osteoclast activity partly through isoform-specific interactions","volume":"7","author":"Roy","year":"2024","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.blre.2025.101305_bb0235","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/ijms18122740","article-title":"Role of galectins in multiple myeloma","volume":"18","author":"Storti","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101305_bb0240","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","article-title":"Osteoblast suppression in multiple myeloma bone disease","volume":"13","author":"Adamik","year":"2018","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 inhibition reverses multiple myeloma-induced epigenetic suppression of osteoblast differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0260","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/aps.2012.182","article-title":"Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo","volume":"34","author":"Xu","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.blre.2025.101305_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9087","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","volume":"11","author":"Liu","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2025.101305_bb0270","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: where we are and where we need to go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101305_bb0275","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in multiple myeloma: from bench to bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0285","first-page":"37","article-title":"Non-coding RNAs in multiple myeloma bone disease pathophysiology","volume":"6","author":"Raimondi","year":"2020","journal-title":"Noncod RNA"},{"key":"10.1016\/j.blre.2025.101305_bb0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","article-title":"Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis","volume":"12","author":"Raimondo","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0295","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2017010801","article-title":"Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss","volume":"1","author":"Zahoor","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101305_bb0300","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/cancers12020449","article-title":"Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma","volume":"12","author":"Raimondo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101305_bb0305","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7150\/thno.27550","article-title":"Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.blre.2025.101305_bb0310","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41388-018-0359-0","article-title":"Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2025.101305_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113080","article-title":"lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts","volume":"142","author":"Song","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2025.101305_bb0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","article-title":"RANKL as the master regulator of osteoclast differentiation","volume":"39","author":"Takayanagi","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.blre.2025.101305_bb0325","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ejh.12436","article-title":"The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma","volume":"94","author":"Gan","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0330","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0335","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0340","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/leu.2015.228","article-title":"Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma","volume":"30","author":"Prabhala","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0345","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/bonekey.2012.135","article-title":"Mechanisms of multiple myeloma bone disease","volume":"1","author":"Galson","year":"2012","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.blre.2025.101305_bb0350","first-page":"938","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF","volume":"48","author":"Hemingway","year":"2011","journal-title":"IGF I IGF II Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0355","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0360","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0365","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.18632\/oncotarget.2633","article-title":"LIGHT\/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease","volume":"5","author":"Brunetti","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0370","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3389\/fimmu.2018.02459","article-title":"LIGHT\/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens","volume":"9","author":"Brunetti","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101305_bb0375","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","article-title":"Inhibition of transforming growth factor-beta activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma","volume":"186","author":"Lu","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2025.101305_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2025.101305_bb0385","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1038\/s41467-024-51442-2","article-title":"The TGFbeta type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial","volume":"15","author":"Malek","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0390","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3606","article-title":"Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models","volume":"34","author":"Paton-Hough","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0395","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin a promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101305_bb0400","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0405","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0410","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.3324\/haematol.2015.124511","article-title":"Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease","volume":"100","author":"Westhrin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0415","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1038\/s41467-019-12296-1","article-title":"Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease","volume":"10","author":"Gooding","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0420","article-title":"The critical role of IL-34 in osteoclastogenesis","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2025.101305_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1099696","article-title":"Interleukin-34 and immune checkpoint inhibitors: unified weapons against cancer","volume":"13","author":"Alshaebi","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0430","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2018020008","article-title":"A role for IL-34 in osteolytic disease of multiple myeloma","volume":"3","author":"Baghdadi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101305_bb0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0440","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0445","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.blre.2025.101305_bb0450","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1517\/14728222.2011.586634","article-title":"CCR1 as a target for multiple myeloma","volume":"15","author":"Vallet","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.blre.2025.101305_bb0455","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0460","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ajpath.2016.04.003","article-title":"Effects of IL-8 up-regulation on cell survival and Osteoclastogenesis in multiple myeloma","volume":"186","author":"Herrero","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2025.101305_bb0465","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4337","article-title":"Semaphorins and plexins as therapeutic targets","volume":"13","author":"Worzfeld","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2025.101305_bb0470","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","article-title":"Suppression of bone formation by osteoclastic expression of semaphorin 4D","volume":"17","author":"Negishi-Koga","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101305_bb0475","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-018-0075-6","article-title":"Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0480","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.4049\/jimmunol.163.10.5723","article-title":"Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation","volume":"163","author":"Barille","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2025.101305_bb0485","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1179\/1607845415Y.0000000043","article-title":"Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma","volume":"21","author":"Urbaniak-Kujda","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101305_bb0490","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1172\/JCI80276","article-title":"Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease","volume":"126","author":"Fu","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101305_bb0495","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101305_bb0500","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","article-title":"The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease","volume":"14","author":"Fu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0505","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2006.12.002","article-title":"Signal integration and diversification through the p62 scaffold protein","volume":"32","author":"Moscat","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.blre.2025.101305_bb0510","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2008-08-173948","article-title":"Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation","volume":"113","author":"Hiruma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0515","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2025.101305_bb0520","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2011.09.026","article-title":"Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases","volume":"314","author":"Hussein","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2025.101305_bb0525","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/jbmr.4398","article-title":"Rictor is a novel regulator of TRAF6\/TRAF3 in osteoclasts","volume":"36","author":"Xu","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0530","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/15548627.2023.2208931","article-title":"Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease","volume":"20","author":"Leng","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.blre.2025.101305_bb0535","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/0008-5472.CAN-06-4361","article-title":"Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma","volume":"67","author":"Vanderkerken","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0540","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ctrv.2012.03.004","article-title":"Therapeutic approaches to myeloma bone disease: an evolving story","volume":"38","author":"Longo","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2025.101305_bb0545","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3324\/haematol.2019.234476","article-title":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma","volume":"106","author":"Teramachi","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0550","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","article-title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma","volume":"29","author":"Hiasa","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0555","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.14388","article-title":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma","volume":"180","author":"Teramachi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0560","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","article-title":"Role of Bruton\u2019s tyrosine kinase in myeloma cell migration and induction of bone disease","volume":"88","author":"Bam","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0565","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","article-title":"Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma","volume":"120","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0570","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1083\/jcb.201207142","article-title":"Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin","volume":"200","author":"Albers","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2025.101305_bb0575","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101305_bb0580","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101305_bb0585","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of Sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0590","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","article-title":"Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment","volume":"67","author":"Giuliani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0595","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10428194.2013.820288","article-title":"Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease","volume":"55","author":"Kristensen","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101305_bb0600","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0605","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0610","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0615","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0620","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0625","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0630","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2014-12-613968","article-title":"Myeloma cell-derived Runx2 promotes myeloma progression in bone","volume":"125","author":"Trotter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0635","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0640","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0645","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0650","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.blre.2025.101305_bb0655","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","article-title":"The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth","volume":"114","author":"Pennisi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101305_bb0660","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0665","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae093","article-title":"Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease","volume":"8","author":"Evans","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.blre.2025.101305_bb0670","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0675","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3389\/fimmu.2018.02467","article-title":"Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy","volume":"9","author":"Toscani","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101305_bb0680","article-title":"The mechanosensory role of osteocytes and implications for bone health and disease states","volume":"9","author":"Choi","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.blre.2025.101305_bb0685","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41413-020-0099-y","article-title":"Molecular mechanosensors in osteocytes","volume":"8","author":"Qin","year":"2020","journal-title":"Bone Res"},{"key":"10.1016\/j.blre.2025.101305_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115998","article-title":"Suppression of cancer-associated bone loss through dynamic mechanical loading","volume":"150","author":"Pagnotti","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0695","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3324\/haematol.2021.278295","article-title":"Mechanical unloading aggravates bone destruction and tumor expansion in myeloma","volume":"107","author":"Tanimoto","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0700","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.3390\/ijms22052375","article-title":"Multiple myeloma bone disease: implication of MicroRNAs in its molecular background","volume":"22","author":"Papanota","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101305_bb0705","doi-asserted-by":"crossref","first-page":"19589","DOI":"10.18632\/oncotarget.7319","article-title":"Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0710","doi-asserted-by":"crossref","first-page":"27343","DOI":"10.18632\/oncotarget.4398","article-title":"Inhibition of miR-21 restores RANKL\/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts","volume":"6","author":"Pitari","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0715","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/15476286.2015.1094600","article-title":"Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma","volume":"12","author":"Xu","year":"2015","journal-title":"RNA Biol"},{"key":"10.1016\/j.blre.2025.101305_bb0720","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41375-018-0161-6","article-title":"Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche","volume":"32","author":"Tsukamoto","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0725","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-024-02168-z","article-title":"Che-1\/miR-590-3p\/TAZ axis sustains multiple myeloma disease","volume":"38","author":"Bruno","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0730","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101305_bb0735","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0740","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0745","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0750","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101305_bb0755","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garcia-Sanz","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0760","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1359\/jbmr.2003.18.2.231","article-title":"Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission","volume":"18","author":"Roux","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0765","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0770","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0775","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The proteasome inhibitor Bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors","volume":"31","author":"Toscani","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0780","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","article-title":"The effects of proteasome inhibitors on bone remodeling in multiple myeloma","volume":"86","author":"Zangari","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.blre.2025.101305_bb0785","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0790","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.4807","article-title":"Increased bone volume by Ixazomib in multiple myeloma: 3-month results from an open label phase 2 study","volume":"38","author":"Diaz-delCastillo","year":"2023","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0795","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"issue":"387\u201397","key":"10.1016\/j.blre.2025.101305_bb0800","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0805","doi-asserted-by":"crossref","first-page":"56598","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0810","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.23577","article-title":"The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed\/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group","volume":"89","author":"Terpos","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0815","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ijc.32125","article-title":"Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma","volume":"145","author":"Terpos","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101305_bb0820","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.25392","article-title":"Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: effects on survival and bone outcomes in the absence of bisphosphonates","volume":"94","author":"Terpos","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0825","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-020-0297-2","volume":"10","author":"Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101305_bb0830","first-page":"13","article-title":"Carfilzomib improves bone metabolism in patients with advanced relapsed\/refractory multiple myeloma: results of the CarMMa study","author":"Terpos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101305_bb0835","first-page":"14","article-title":"Daratumumab improves bone turnover in relapsed\/refractory multiple myeloma; Phase 2 study \u201cREBUILD\u201d","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101305_bb0840","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0845","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/hematolrep16030051","article-title":"First-line combination with proteasome inhibitor-based treatment and Zoledronic acid is effective in reducing later fractures in multiple myeloma irrespective of multiple myeloma bone disease at diagnosis","volume":"16","author":"Eskelinen","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2025.101305_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104429","article-title":"Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"201","author":"Kuruvilla","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101305_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1581264","article-title":"Editorial: promotion of quality of life in oncology patients and survivors through physical activity","volume":"15","author":"Hardcastle","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0860","doi-asserted-by":"crossref","first-page":"153","DOI":"10.6004\/jadpro.2023.14.2.5","article-title":"Physical activity in multiple myeloma: a review of the current literature","volume":"14","author":"Hillengass","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.blre.2025.101305_bb0865","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ejh.14215","article-title":"Exercise in newly diagnosed patients with multiple myeloma: a randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of life","volume":"113","author":"Larsen","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101305_bb0870","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","article-title":"A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma","volume":"15","author":"Fulciniti","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0875","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101305_bb0880","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12935-014-0132-6","article-title":"Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease","volume":"14","author":"Fu","year":"2014","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.blre.2025.101305_bb0885","doi-asserted-by":"crossref","first-page":"30712","DOI":"10.18632\/oncotarget.8750","article-title":"SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma","volume":"7","author":"Heusschen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0890","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2014.12.015","article-title":"The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma","volume":"39","author":"Martin","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101305_bb0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199517","article-title":"ARQ-197, a small-molecule inhibitor of c-met, reduces tumour burden and prevents myeloma-induced bone disease in vivo","volume":"13","author":"Lath","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2025.101305_bb0900","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2017.185397","article-title":"Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease","volume":"103","author":"Muller","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101305_bb0905","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fendo.2018.00115","article-title":"Kisspeptin and cancer: molecular interaction, biological functions, and future perspectives","volume":"9","author":"Ciaramella","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.blre.2025.101305_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155087","article-title":"The KISS1 receptor as an in vivo microenvironment imaging biomarker of multiple myeloma bone disease","volume":"11","author":"Dotterweich","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2025.101305_bb0915","first-page":"47","article-title":"Interactions between kisspeptin and bone: cellular mechanisms, clinical evidence, and future potential","volume":"1540","author":"Mills","year":"2024","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2025.101305_bb0920","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0925","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jbmr.4809","article-title":"Multi-targeting DKK1 and LRP6 prevents bone loss and improves fracture resistance in multiple myeloma","volume":"38","author":"Simic","year":"2023","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2025.101305_bb0930","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/s41467-022-31997-8","article-title":"Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation","volume":"13","author":"Yu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101305_bb0935","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1541-7786.MCR-17-0606","article-title":"Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression","volume":"16","author":"Gowda","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.blre.2025.101305_bb0940","doi-asserted-by":"crossref","first-page":"41827","DOI":"10.18632\/oncotarget.18103","article-title":"Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment","volume":"8","author":"Shay","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101305_bb0945","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41392-023-01467-8","article-title":"Targeting strategies for bone diseases: signaling pathways and clinical studies","volume":"8","author":"Xu","year":"2023","journal-title":"Sign Transduct Target Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:36:11Z","timestamp":1766079371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":189,"alternative-id":["S0268960X25000505"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101305","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101305"}}